Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

根据最新的SEC文件显示，知名投资公司EcoR1 Capital, LLC在三天内大幅增持了Zymeworks Inc. (NASDAQ: ZYME )的股份，收购金额约为1310万美元。根据 InvestingPro 数据，这家制药公司目前市值为8.72亿美元，其现金储备超过债务。

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

In a report released today, Derek Archila from Wells Fargo maintained a Hold rating on Zymeworks (ZYME – Research Report), with a price target ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Zymeworks (NYSE:ZYME – Free Report) had its target price raised by Citigroup from $18.00 to $19.00 in a report released on ...

04. Zymeworks Inc. (ZYME) 2024年第四季度财报电话会议：Zymeworks是一家专注于开发多功能生物治疗药物的临床阶段生物技术公司，其2024年净亏损1.227亿美元，收入从2023年的7600万美元略增至7630万美元。公司拥有多个临床前和临床阶段的项目，包括ZW191（FRα靶向ADC）和ZW251（GPC3靶向ADC），后者在肝细胞癌模型中表现出色，预计2025年 ...

Zymeworks (ZYME) has disclosed a new risk, in the Innovation / R&D category. Zymeworks faces a significant business risk in the development of ...

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...

Welcome to Zymeworks fourth quarter and year-end 2024 results conference call and webcast. As a reminder, all participants are in listen-only mode and the conference is being recorded. (Operator ...

周四，花旗分析师将纳斯达克上市公司Zymeworks（NASDAQ:ZYME）的目标股价从此前的18美元上调至19美元，同时重申对该公司股票的买入评级。目前该股交易价格为13.18美元，低于分析师12美元至30美元的目标区间。根据 InvestingPro 数据显示，尽管该公司仍处于开发阶段，但其整体财务健康状况评分为"良好"，表明基本面稳健。

Zymeworks Inc (ZYME) navigates a challenging year with strategic pivots and robust partnership earnings, despite increased ...